Expression of CHOP in Squamous Tumor of the Uterine Cervix

Hyun Hee Chu¹ - Jun Sang Bae¹
Kyoung Min Kim¹ - Ho Sung Park¹
Dong Hyu Cho² - Kyu Yun Jang¹,³
Woo Sung Moon¹,³
Myoung Jae Kang¹
Dong Geun Lee¹
Myoung Ja Chung¹,³,⁴

Departments of ¹Pathology and ²Obstetrics and Gynecology, Chonbuk National University Medical School, ³Research Institute for Endocrine Sciences, ⁴Research Institute for Medical Sciences, Chonbuk National University, Jeonju, Korea.

Received: June 25, 2012
Revised: September 3, 2012
Accepted: September 4, 2012

Corresponding Author
Myoung Ja Chung, M.D.
Department of Pathology, Chonbuk National University Medical School, 567 Baekje-daero, Deokjin-gu, Jeonju 561-756, Korea.
Tel: +82-63-270-3072
Fax: +82-63-270-3135
E-mail: mjchung@jbnu.ac.kr

Background: High-risk human papillomavirus (HR-HPV) infection and abnormal p53 expression are closely involved in carcinogenesis of squamous cell carcinoma (SqCC) of uterine cervix. Recent studies have suggested that virus-induced endoplasmic reticulum (ER) stress modulates various cell survival and cell death signaling pathways. The C/EBP homologous protein (CHOP) is associated with ER stress-mediated apoptosis and is also involved in carcinogenesis of several human cancers. We hypothesized that CHOP is involved in the carcinogenesis of uterine cervical cancer in association with HR-HPV and/or p53. Methods: Immunohistochemistry was used to analyze CHOP and p53 protein expression of tissue sections from 191 patients with invasive cancer or preinvasive lesions of the uterine cervix (61 cases of SqCC, 66 cases of cervical intraepithelial neoplasia [CIN] III, and 64 cases of CIN I). Results: CHOP was expressed in 59.4% of CIN I, 48.5% of CIN III, and 70.5% of SqCC cases. It was also significantly more frequent in invasive SqCC than in preinvasive lesions (p = 0.042). Moreover, CHOP expression significantly correlated with HR-HPV infection and p53 expression (p = 0.009 and p = 0.038, respectively). Conclusions: Our results suggest that CHOP is involved in the carcinogenesis of the uterine cervix SqCC via association with HR-HPV and p53.

Key Words: Transcription factor CHOP; Uterine cervical neoplasms; DNA probes, HPV; Tumor suppressor protein p53

The endoplasmic reticulum (ER) is an essential intracellular organelle that serves important cellular functions. One of its major functions is to ensure proper folding of newly synthesized proteins destined for secretion, the cell surface, or intracellular organelles. Various physiological and pathological conditions lead to the accumulation of unfolded proteins in the ER, a condition referred to as “ER stress.” In response to ER stress conditions, cells activate an intracellular signaling pathway, the unfolded protein response (UPR),¹ which acts to reduce ER stress by activating three adaptive pathways: 1) transcriptional induction of ER chaperones to help protein folding; 2) translational attenuation of protein synthesis, which blocks new protein synthesis; and 3) enhanced degradation of misfolded or unfolded proteins via the ubiquitin-proteasome system.¹⁻³ If the UPR is unable to rescue cells, the cells eventually enter apoptosis via increased C/EBP homologous protein (CHOP) expression or activation of ER-specific caspases. CHOP, also known as growth arrest and DNA damage-inducible protein 153 (GADD153), is a transcription factor induced by DNA damage and is activated in response to ER stress.⁴ CHOP plays an important role in ER stress-induced apoptosis and is widely used as an ER stress marker. Moreover, increased CHOP expression has been reported in some malignant tumors.¹⁻³ On the other hand, p53 is one of the important apoptosis-related genes and is also involved in many other cellular processes such as cell cycle progression, DNA repair, differentiation, senescence, and chromatin remodeling.⁸ Impaired p53-dependent apoptosis due to high-risk human papillomavirus (HR-HPV) has been known as one of the key mechanisms of cervical carcinogenesis. Interestingly, CHOP is one of the many p53 target genes⁹,¹⁰ according to human cell studies.

Cervical cancer is the second most common type of cancer in women worldwide.¹¹ Human papillomaviruses (HPV) are the etiologic agents responsible for cervical cancer. Over 100 differ-
ent types of HPV have been identified based on their DNA sequence. HPV types such as HPV 16 and HPV 18 are high oncogenic types. More than 99% of cervical cancers contain DNA from at least one HR-HPV type, and approximately 70% contain HPV 16 or 18. However, experimental and epidemiological evidences indicate that HR-HPV is not sufficient to induce tumor development. Other factors have to be involved in the progression of infected cells to full neoplastic transformation. Recent studies have shown that ER stress may facilitate viral replication or pathogenesis. The ER is an essential organelle for viral replication and maturation. A large number of viral proteins are produced in infected cells, where unfolded or misfolded proteins activate the ER stress response. There are some reports regarding the role of ER stress in HPV infection. Accordingly, ER stress responses were repressed in HPV 16 infected genital keratinocytes. ER protein 57 (ERp57), one of the ER stress markers, was induced in HPV 16 positive squamous cell carcinoma (SqCC) of uterine cervix. Based on these reports, we hypothesized that CHOP is involved in the carcinogenesis of uterine cervical cancer in association with HR-HPV and/or p53. To test this, we conducted immunohistochemical studies to assess CHOP and p53 expression in cervical intraepithelial neoplasms (CIN) and invasive SqCC of the uterine cervix. We also investigated the association between CHOP expression and HR-HPV infection.

MATERIALS AND METHODS

Patients and specimens

We selected 191 female patients with CIN or invasive SqCC for the study. Tissues were obtained from 61 invasive SqCC, 66 grade 3 CIN (CIN 3), and 64 CIN 1 patients who underwent surgery at the Department of Obstetrics and Gynecology, Chonbuk National University Hospital between June 2005 and June 2011. For the present study, we selected patients with available tissue blocks and who had PAP smear and HR-HPV tests before tissue collection. All cytological specimens were taken without prior tissue collection. All cytological specimens were taken within 60 days prior to the tissue collection date. To investigate the association between HPV infection and CHOP expression, we incorporated half of the HPV negative cases into each group. Among the 130 CIN cases, 64 were HR-HPV negative and 66 cases were HR-HPV positive. However, a small number of HPV-negative cases (15% of invasive cancer) were included in the invasive SqCC group because of the high prevalence of HPV infection in cervical cancer. Clinicopathological information was obtained through a computerized tumor registry database. Thirty cases of normal cervical tissues with no HPV infection were used as normal control tissue. Histological typing for CIN was performed according to the three-tiered classification of the World Health Organization. The mean ages of the patient groups at the time of diagnosis were 34.53 years for CIN 1, 39.68 years for CIN 3, and 53.43 years for SqCC (range for the entire sample, 26 to 85 years). This study was approved by the Human Ethics Committee of Chonbuk National University Medical School. Informed consent was provided according to the Declaration of Helsinki.

Determination of HPV infection

Endo/exocervical specimens were obtained by a cytobrush. The presence of HPV infection was determined using the Hybrid Capture system (Digene Inc., Gaithersburg, MD, USA). The Hybrid Capture test is a nucleic acid hybridization assay in which specimens containing the target DNA hybridize with a specific HPV RNA probe mixture, including probes for the following HR-HPV types-16/18/31/33/35/45/51/52/56. The resultant RNA : DNA hybrids are captured onto the surface of a microplate well coated with antibodies specific for RNA : DNA hybrids. Immobilized hybrids are then reacted with alkaline phosphatase conjugated antibodies specific for the DNA : RNA hybrids, and detected with a chemiluminescent substrate. Emitted light is measured by a luminometer as relative light units (RLU). Samples were classified as positive for HR-HPV if the RLU value was > 1.0.

Immunohistochemistry

Immunohistochemical studies were performed on 5-μm sections of formalin-fixed, paraffin-embedded tissue specimens. All specimens were examined with the Dako Envision system, which uses dextran polymers conjugated with horseradish peroxidase (Dako, Carpinteria, CA, USA). Antigen retrieval was achieved by incubating tissue sections in boiling 10 μmol/L citrate buffer (pH 6.0) for 10 minutes in a microwave oven prior to incubation with primary antibodies against CHOP. Tissue sections for p53 detection were incubated for three 5-minute intervals in a scientific cooker for antigen retrieval (10 μmol/L citrate buffer, pH 6.0). After blocking endogenous peroxidase, the sections were incubated with Protein Block Serum-Free (Dako) at room temperature for 10 minutes to block non-specific staining. Thereafter, sections were incubated for 2 hours at room temperature with mouse anti-p53 monoclonal antibody (1:100, Dako) and with mouse anti-CHOP monoclonal antibody (1:50, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
overnight at 4°C. Peroxidase activity was detected using the enzyme substrate 3-amino-9-ethyl carbazole. Negative control sections were treated in the same way except that they were incubated with Tris-buffered saline without primary antibody.

All immunostained sections were evaluated by two pathologists (M.J. Chung and H.H. Chu) who were blinded to the patients’ clinicopathological information. CHOP assays were interpreted for immunoreactivity according to the intensity of staining and percentage of positive cells. The intensity of cytoplasmic staining was classified into four categories: no immunostaining (0), weak immunostaining (1), moderate immunostaining (2), and intense immunostaining (3). The percentage of positive cells was scored as 0 (<30%), 1 (>30% and ≤50%), and 2 (>50%). The sum index was obtained by totaling the scores of intensity and the percentages. If the final score was ≥3, the tumor was considered positive; if otherwise, the tumor was considered negative. Nuclear staining in >10% of the neoplastic cells was considered positive for p53 expression.18,19

Statistical analysis

SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. The association between the staining index and other clinicopathological variables was analyzed using Pearson’s chi-square test. Differences were considered significant when p-values were <0.05.

**RESULTS**

CHOP and p53 expression in association with clinicopathological parameters

Immunohistochemical stainings of CHOP and p53 in CIN and invasive SqCC are shown in Fig. 1. CHOP and p53 immunoreactivities were observed primarily in the cytoplasm and nuclei, respectively. The basal layer of normal cervical mucosa showed very weak immunoreactivity to CHOP and p53. Therefore, all cases of normal cervical tissues were negative for CHOP and p53. The associations between protein expression and clinicopathologic parameters are summarized in Table 1. Lesions of invasive SqCC showed significantly more frequent CHOP expression compared to those of CIN (70.5% vs 53.8%, p = 0.04). CHOP expression was significantly higher in CIN (53.8%) than in control tissues (0%). However, there was no gradual increase in CHOP expression along the continuum of CIN. CHOP expression rates were higher in CIN 1 compared with those in CIN 3 (59.4% vs 48.5%, p = 0.224) (data not shown). Meanwhile, p53 expression gradually increased with tumor progression and was significantly higher in invasive carcinomas (91.8%) than in CIN (70.8%) (p = 0.001). Lesions of CIN 3 showed significantly more frequent p53 expression compared to those of CIN 1 (84.8% vs 57.8%, p < 0.001). CHOP expression was correlated with p53 expression (p = 0.038) (Table 2).

CHOP expression in association with HPV infection

Overall, the study of 191 cases of squamous lesions revealed that CHOP expression correlated significantly with HR-HPV infection (p = 0.009) (Table 1). When we conducted correlation analysis after sorting the tumors by histopathological grade, CHOP expression correlated significantly with HPV infection for CIN 1 and invasive cancer (p = 0.024 and p = 0.007, respectively) (Table 3). On the other hand, we found no correlation between HPV infection and CHOP expression in CIN 3 (p = 0.460).

**DISCUSSION**

Conditions that induce ER stress, such as hypoxia, oxidative stress, nutrient deprivation, and changes in pH (acidosis) are frequently encountered in tumor cells.20 Several studies have reported evidence of UPR activation in various tumors. Therefore, it is important to establish the pathway of UPR activation in tumors or the role of UPR activation in tumorigenesis. Although HPV infection is recognized as the main pathogenetic factor of cervical cancer, it is not sufficient to induce tumor development. In the present study, we examined CHOP expression in uterine cervical tumor and its correlation with HR-HPV and/or p53. We demonstrated that lesions of invasive SqCC showed significantly more frequent CHOP expression compared to those of CIN, and CHOP expression significantly correlated with HR-HPV infection and p53 expression.

There are a few studies which have considered the clinical relevance of CHOP expression in human cancers. The present study showed that relative to the normal cervix, CHOP expression increased in CIN and invasive cancer, and was significantly more frequent in invasive cancer than in CIN. These results are similar to the findings of our earlier study21 and to those found by others.22 Accordingly, Rask et al.22 found that CHOP overexpression is correlated with cancer invasiveness and unfavorable clinicopathological factors in colorectal cancer. We also observed that CHOP expression was significantly less frequent in premalignant glandular lesion (atypical adenomatous hyperplasia) than in invasive adenocarcinoma of lung.21 In contrast, increased CHOP expression has been associated with lower tumor stage in colon cancer, and with a higher survival rate in melano-
Fig. 1. Immunohistochemical staining of the C/EBP homologous protein (CHOP) and p53 in cervical intraepithelial neoplasias (CIN) and invasive squamous cell carcinoma (SqCC). (A-F) CHOP; (G-L) p53.
De Marco et al.\textsuperscript{16} reported that ERp57, an ER stress marker, was significantly elevated in squamous cell carcinoma tissues compared with both dysplastic and control tissues of uterine cervix. Based on these results, we suggest that CHOP expression might be involved in tumorigenesis of uterine cervical squamous tumors. Further studies are needed to elucidate the role of CHOP in the development or progression of cancer.

Accumulating evidence suggests that viruses, including HPV, manipulate the programs emanating from the ER in a complex manner, which in turn, may facilitate viral replication or pathogenesis.\textsuperscript{14,15} HPV16 E5 represses the cellular ER stress response in genital keratinocytes.\textsuperscript{15} HPV 16 E5 is a HPV 16 transforming protein, which localizes predominantly in the ER, and can enhance cell immortalization by E6E7. Accordingly, repression of ER stress response may assist the persistence of viral infection. De Marco et al.\textsuperscript{16} reported that the expression of ER stress marker was significantly increased in HPV 16 positive cancer tissues compared with both dysplastic and control tissue. In the present study, we found that HR-HPV infection correlated significantly with CHOP expression in invasive SqCC. We assume that persistent HPV infection may induce ER stress (and eventually CHOP overexpression), and CHOP overexpression along with apoptosis may be involved in the tumorigenesis of cervical cancer. At any rate, further studies are needed to clarify the role of CHOP overexpression in carcinogenesis of cervical cancer and to identify the mechanism underlying the relationship between HPV infection and CHOP expression.

A well-known abnormal gene expression pattern in cervical cancer is p53 degradation. Unlike most solid tumors, p53 mutation is infrequently found in cervical cancers. In cervical cancers, viral early protein E6 of HR-HPV induces p53 degradation via direct binding to the ubiquitin ligase E6AP, allowing cells to bypass apoptosis and survive with DNA damage; thus, contributing to tumorigenesis.\textsuperscript{23-25} Both CHOP and p53 are as-

Table 1. Correlation between clinicopathological parameters and CHOP and p53 expression in squamous tumors of the uterine cervix

| Characteristics | No. of cases | CHOP expression | p-value | p53 expression | p-value |
|-----------------|-------------|----------------|---------|----------------|---------|
| Age (yr)        |             |                |         |                |         |
| <50             | 115         | Positive 69 (60.0) Negative 46 (40.0) | 0.772   | Positive 88 (76.5) Negative 27 (23.5) | 0.541   |
| ≥50             | 76          | Positive 44 (57.9) Negative 32 (42.1) | 0.040   | Positive 61 (80.3) Negative 15 (19.7) | 0.001   |
| Histologic grade|             |                |         |                |         |
| CIN             | 130         | Positive 70 (53.8) Negative 60 (46.2) | 0.009   | Positive 93 (71.5) Negative 37 (28.5) | 0.019   |
| SqCC            | 61          | Positive 42 (70.5) Negative 18 (29.5) | 0.393   | Positive 56 (81.8) Negative 5 (18.2) | 0.775   |
| HR-HPV          |             |                |         |                |         |
| Negative        | 79          | Positive 38 (48.1) Negative 41 (51.9) | 0.393   | Positive 55 (69.6) Negative 24 (30.4) | 0.019   |
| Positive        | 112         | Positive 75 (67.0) Negative 37 (33.0) | 0.775   | Positive 94 (83.9) Negative 18 (16.1) | 0.019   |
| FIGO stage      |             |                |         |                |         |
| IA              | 27          | Positive 18 (66.7) Negative 9 (33.3) | 0.258   | Positive 25 (92.6) Negative 2 (7.4) | 0.038   |
| IB              | 30          | Positive 21 (70.0) Negative 9 (30.0) | 0.303   | Positive 27 (90.0) Negative 3 (10.0) | 0.038   |
| IIB             | 4           | Positive 4 (100) Negative 0 (0) | 0.000   | Positive 4 (100) Negative 0 (0) | 0.000   |

Values are presented as number (%).
CHOP, C/EBP homologous protein; CIN, cervical intraepithelial neoplasms; SqCC, squamous cell carcinoma; HR-HPV, high-risk human papillomavirus; FIGO, International Federation of Gynecology and Obstetrics.

Table 2. Association between CHOP and p53 expression in squamous tumors of the uterine cervix

| Characteristics | CHOP expression | p-value |
|-----------------|----------------|---------|
| P53 expression  |                |         |
| Negative        | Positive 19 (45.2) Negative 23 (54.8) | 0.038   |
| Positive        | Positive 94 (63.1) Negative 55 (36.9) | 0.038   |

Values are presented as number (%).
CHOP, C/EBP homologous protein.

Table 3. Association between CHOP expression and HPV status in CIN and invasive squamous cell carcinoma of the uterine cervix

| Characteristics | No. of cases | CHOP expression | p-value |
|-----------------|-------------|----------------|---------|
| CIN 1           | 64          |                |         |
| HR-HPV (-)      | 33          | Positive 15 (45.5) Negative 18 (54.5) | 0.024   |
| HR-HPV (+)      | 31          | Positive 23 (74.2) Negative 8 (25.8) | 0.024   |
| CIN 3           | 66          |                |         |
| HR-HPV (-)      | 31          | Positive 17 (54.8) Negative 14 (45.2) | 0.06    |
| HR-HPV (+)      | 35          | Positive 15 (42.9) Negative 20 (57.1) | 0.007   |
| Invasive SqCC   | 61          |                |         |
| HR-HPV (-)      | 15          | Positive 6 (40.0) Negative 9 (60.0) | 0.67    |
| HR-HPV (+)      | 46          | Positive 37 (80.4) Negative 9 (19.6) | 0.024   |

Values are presented as number (%).
CHOP, C/EBP homologous protein; HPV, human papillomavirus; CIN, cervical intraepithelial neoplasms; HR-HPV, high-risk human papillomavirus; SqCC, squamous cell carcinoma.
associated with apoptosis and there are reports indicating that CHOP is a novel p53 target gene. The present study showed that CHOP expression significantly correlated with p53 expression indicating the link between CHOP and p53 in cervical cancer. In contrast, a previous study showed that environmental stress causes DNA damage, resulting in the expression of p53 and GADD genes and GADD153 (CHOP) expression was independent of p53. Indeed, the exact mechanism underlying the relationship between CHOP and p53 expression should be clarified.

In conclusion, our results suggest that CHOP is involved in tumorigenesis of squamous cell tumors of the uterine cervix via association with HR-HPV and p53. Our data also indicate that CHOP expression may also be associated with tumor progression. Additional studies are required to determine the exact molecular mechanisms explaining the roles of CHOP in the development and progression of cervical cancer, and the relationship between CHOP expression and HPV infection and/or p53 expression.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by the National Research Foundation of Korea Grant funded by the Korean Government (No. 2011-0028223). The biospecimens for this study were partly provided by the Biobank of Chonbuk National University Hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs.

REFERENCES

1. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-29.
2. Wu J, Kaufman RJ. From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ 2006; 13: 374-84.
3. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-89.
4. Luethy JD, Holbrook NJ. Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage. Cancer Res 1992; 52: 5-10.
5. Korabiowska M, Cordon-Cardo C, Betke H, et al. GADD153 is an independent prognostic factor in melanoma: immunohistochemical and molecular genetic analysis. Histol Histopathol 2002; 17: 805-11.
6. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363: 640-4.
7. Forus A, Flarevas NA, Maelandsmo GM, Fodstad O, Myklebost O. The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas. Cancer Genet Cytogenet 1994; 78: 165-71.
8. Buitrago-Pérez A, Garaulet G, Vázquez-Carballo A, Paramio JM, García-Escudero R. Molecular signature of HPV-induced carcinogenesis: pRb, p53 and gene expression profiling. Curr Genomics 2009; 10: 26-34.
9. Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman KG. Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis. Cell Death Differ 2007; 14: 411-21.
10. Seth A, Giunta S, Franceschil C, Kola I, Venanzoni MC. Regulation of the human stress response gene GADD153 expression: role of ETS1 and FLI-1 gene products. Cell Death Differ 1999; 6: 902-7.
11. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-8.
12. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27.
13. Hamid NA, Brown C, Gaston K. The regulation of cell proliferation and DNA damage response. Annu Rev Biochem 2005; 74: 53-60.
14. De Marco F, Bucaj E, Foppoli C, et al. Oxidative stress in HPV-driven viral carcinogenesis: redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues. PLoS One 2012; 7: e34366.
15. Guha D, Chatterjee R. Human papillomavirus detection and genotyping by hybrid capture II in the cervical smears of women at high-risk for HIV infection. Int J Hum Genet 2006; 6: 185-90.
16. Park CS, Joo IS, Song SY, Kim DS, Bae DS, Lee JH. An immunohistochemical analysis of heat shock protein 70, p53, and estrogen receptor status in carcinoma of the uterine cervix. Gynecol Oncol 1999; 74: 53-60.
17. Zong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5.
18. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004; 4: 966-101.
77.

21. Kim KM, Yu TK, Chu HH, et al. Expression of ER stress and autophagy-related molecules in human non-small cell lung cancer and premalignant lesions. Int J Cancer 2012; 131: E362-70.

22. Rask K, Thörn M, Pontén F, et al. Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBBeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer 2000; 86: 337-43.

23. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505.

24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.

25. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.

26. O’Reilly MA, Staversky RJ, Watkins RH, Maniscalco WM, Keng PC. p53-independent induction of GADD45 and GADD153 in mouse lungs exposed to hyperoxia. Am J Physiol Lung Cell Mol Physiol 2000; 278: L552-9.